deltatrials
Completed PHASE1 INTERVENTIONAL 3-arm NCT04477512

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

A Phase 1b Clinical Trial of Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Sponsor: Bristol-Myers Squibb

Conditions Metastatic Hormone Refractory Prostate Cancer
Interventions Abiraterone acetate Cabozantinib Nivolumab Peripheral blood collection Prednisone
Updated 17 times since 2020 Last updated: Nov 10, 2025 Started: Feb 19, 2021 Primary completion: Sep 9, 2021 Completion: Sep 10, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Metastatic Hormone Refractory Prostate Cancer and is currently completed. Bristol-Myers Squibb leads this study, which shows 17 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Dec 2021 · 7 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Apr 2023 · 9 months · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Dec 2023 · 7 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Sep 2025 · 9 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

17 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Sep 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Dec 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 12 earlier versions

  1. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  2. May 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE1

  4. Jul 2022 — Apr 2023 [monthly]

    Recruiting PHASE1

  5. Apr 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  6. Dec 2021 — Apr 2022 [monthly]

    Recruiting PHASE1

  7. May 2021 — Dec 2021 [monthly]

    Recruiting PHASE1

  8. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  9. Mar 2021 — Apr 2021 [monthly]

    Not Yet Recruiting PHASE1

  10. Jan 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE1

  11. Nov 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE1

  12. Aug 2020 — Nov 2020 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Exelixis
  • Washington University School of Medicine
Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations